London-based Oyster Therapeutics has announced the successful completion of a $60 million Series A funding round, with strategic participation from CE-Ventures, the venture capital arm of the UAE-based Crescent Enterprises. This funding aims to accelerate the development of innovative treatments for neurodegenerative diseases, with an initial focus on Alzheimer's disease and conditions associated with the accumulation of the tau protein.
What does Oyster Therapeutics' technology offer?
The company relies on its proprietary technology platform called SELFTAC, which is designed to overcome the size limitations faced by traditional protein degradation technologies. The platform works by enabling smaller components to cross biological membranes before self-assembling inside the cell, which enhances the drug's ability to penetrate the central nervous system and increases the bioavailability of oral treatments.
Why is this news important?
This investment represents a qualitative expansion of the CE-Ventures portfolio in the life sciences sector, as the company moves from traditional investments to targeted protein degradation technologies. For patients, the significance lies in the design of the company's lead drug candidate as an oral treatment capable of crossing the blood-brain barrier, making it a more practical therapeutic approach compared to treatments that require direct injections or complex procedures.
Research collaboration and next steps
In parallel with the funding, Oyster Therapeutics has entered into a research agreement with Massachusetts General Hospital in the United States. This collaboration aims to deepen the understanding of tau protein biology using patient-derived neuronal cell lines, under the supervision of Dr. Catarina Silva, a leading researcher at the Massachusetts General Institute for Neurodegenerative Disease. The new funds will be used to advance the company's lead drug program toward clinical trials and to further develop the SELFTAC platform, opening new horizons for a generation of drugs targeting central nervous system diseases.